What Consure Medical does

Consure Medical (legal entity: CM Technologies, Inc.) is a privately held medical device company founded in 2012 and headquartered in Carrollton, Texas, with additional offices in New Delhi, India and San Diego, California. The company develops and commercializes fecal management systems for non-ambulatory patients in hospital ICU and critical care settings, where fecal incontinence affects an estimated 9–40% of ICU patients and consumes up to 174 minutes of nursing time per patient per day under traditional management methods. Its portfolio consists of two core products: Qora SMK, a non-balloon stool management kit using a pliable self-conforming stent that exerts up to 73% lower radial force than balloon catheters and is compatible with both tonic and atonic sphincter tone patients; and Qoramatic, an automated stool management system that uses negative pressure suction and a soft silicon receptacle exerting 0 mmHg radial pressure on the rectal mucosa. Both products were developed in collaboration with Stanford University, the All India Institute of Medical Sciences (AIIMS), and IIT Delhi.

The company operates a direct enterprise field sales motion targeting hospital procurement and ICU clinical staff, supported by a VP of Sales, Territory Managers, and a "Request a Free Demo" clinical evaluation program that converts trial deployments into recurring consumable orders. Revenue is generated through hardware sales of Qora SMK and Qoramatic kits to hospitals and large integrated delivery networks (IDNs) in the United States, Europe, and India, with quote-based pricing and no publicly disclosed list prices. Marketing is content-driven through a clinical blog and educational resources, supplemented by LinkedIn, Twitter/X, Facebook, Instagram, and YouTube channels aimed at nurse leaders and hospital decision-makers.

The company is venture-backed, with Accel as the lead institutional investor and board representation (Barath S Subramanian), alongside earlier participation from India Innovation Fund, IAN Group, India Venture Partners, and TR Capital. Consure Medical has positioned its products around three quantifiable claims: a 30% reduction in healthcare-associated complications, three times higher patient eligibility versus balloon catheters, and fewer than five adverse event reports on FDA MAUDE versus 1,500+ for balloon catheter alternatives. The company's stated mission is to help 10 million patients in 10 years.

Name

Consure Medical

Legal name

CM Technologies, Inc.

Website

https://consuremedical.com

Company type

Private

Founded year

2012

Operating status

Operating

Headcount range

11–50 employees

Short description

Consure Medical is a privately held medical device company that develops and sells the Qora SMK and Qoramatic fecal management systems to hospital ICU and critical care units in the United States, Europe, and India.

Ownership category

akta.pro rank

Product category

Fecal Incontinence Management Medical Devices

NAICS

Surgical Appliance and Supplies Manufacturing (339113)

SIC

Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842)

akta.pro primary industry

Single-Use Medical Disposables & Procedure Kits (Drapes, Tubing, Catheters, Syringes, Custom Packs) (HLAHANAG)

akta.pro secondary industry

Incontinence & Urological Supplies (Catheters, Briefs, Ostomy Supplies) (HSABAKAH)

Keywords

• Fecal management devices
• ICU medical devices
• Stool management systems
• Incontinence care products
• Critical care medical equipment

Headquarters

HQ city

New Delhi

HQ country

India

HQ region

Asia

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales, Supply Chain

Revenue model

1. Medical Device Sales - Qora SMK and Qoramatic: Consure Medical generates revenue through the sale of its fecal management medical devices (Qora SMK stool management kits and Qoramatic automated stool management kits) to hospitals, healthcare systems, and clinical facilities. Products are sold directly through a field sales team and offered via free clinical evaluations. The company targets ICU and critical care departments within acute care hospitals.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels7 records

Core offering

Consure Medical manufactures and sells proprietary fecal management medical devices for ICU and critical care settings. Its flagship Qoramatic is an automated stool management kit that uses negative pressure suction and a soft silicone receptacle exerting 0 mmHg radial pressure on the rectal mucosa, eliminating inflation balloons. The Qora SMK (Stool Management Kit) is a non-balloon system that uses a pliable stent/lattice to conform to the rectum with up to 73% lower radial force than balloon catheters. Both products target non-ambulatory patients with fecal incontinence in hospitals and IDNs.

Product overview

Consure Medical offers a portfolio of incontinence management medical devices designed for critically ill patients in ICU settings. The product portfolio consists of two core stool/fecal management systems: Qoramatic (an automated stool management kit using negative pressure suction technology) and Qora SMK (a non-balloon fecal management system using a pliable stent design). Both products address fecal incontinence management challenges by providing alternatives to traditional balloon catheters and absorbent pads, focusing on reducing patient trauma, nurse burden, and hospital-acquired complications.

Differentiator

Problem solved

Functional benefit

Brands

• Qora: Non-balloon fecal management system using a pliable lattice/stent technology for stool containment. Includes Qora SMK (Stool Management Kit).
• Qoramatic

Products and services

• Qoramatic Qoramatic is an industry-first automated stool management system that uses negative pressure suction to proactively divert fecal effluents away from patients. It features a soft silicone indwelling receptacle exerting 0 mmHg radial pressure on rectal mucosa, eliminating inflation balloons. Includes automated irrigation and suction chambers, intelligent LED indicators, and a closed-loop drainage bag designed for accurate output measurement, flatus release valve, and malodor containment. Designed for ICU and critical care use on non-ambulatory patients.
• Qora SMK (Qora Stool Management Kit) Qora SMK is a novel non-balloon fecal management system that uses a pliable self-conforming stent/lattice instead of a high-pressure balloon. The device conforms around the rectal mucosa and moves with peristalsis, exerting up to 73% lower radial force than balloon catheters. It includes a contactless stool sampling port and enables 2X faster fluid delivery for rectal medication administration. Designed for patients with both tonic and atonic sphincter tone.

Named customers1 record

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature7 records

Partnerships

Three partnerships are on record, tiered minor.

• Stanford UniversityminorStrategic or Co-development PartnerStanford University collaborated with Consure Medical in the development of the Qora™ non-balloon-based, self-conforming device technology. Stanford faculty and researchers contributed to the product design and clinical validation process.
• All India Institute of Medical Sciences (AIIMS)minorStrategic or Co-development PartnerAIIMS collaborated with Consure Medical in the development of the Qora™ non-balloon-based, self-conforming device technology, contributing clinical expertise to product design and validation.
• Indian Institute of Technology Delhi (IIT Delhi)minorStrategic or Co-development PartnerIIT Delhi collaborated with Consure Medical in the development of the Qora™ non-balloon-based, self-conforming device technology, contributing technologist expertise to the product platform.

Scale indicators7 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Convatec: Convatec is a global medical products company with a well-established fecal management system (Flexi-Seal) that competes directly with Consure's Qoramatic and Qora SMK in the ICU fecal incontinence category. Both companies target hospital ICU and critical care units with single-use disposable devices addressing the same clinical problem.
• Hollister Incorporated: Hollister makes the Vitala fecal control system, a direct competitor to Consure's non-balloon fecal management devices. Both companies serve the same ICU/critical care customer base with single-use stool management products designed to reduce hospital-acquired complications.
• B. Braun Medical: B. Braun offers the ActiFlo indwelling bowel catheter system, directly competing with Consure's products in ICU fecal management. B. Braun's broader hospital supply portfolio and global distribution give it incumbent leverage in the same accounts Consure targets.
• Coloplast: Coloplast's Peristeen anal irrigation system and broader ostomy/continence portfolio address similar patient populations to Consure, particularly in the urological and bowel management categories. While Coloplast focuses on chronic outpatient use, it overlaps with Consure on the underlying continence management need.

Broad incumbents

• Teleflex: Teleflex manufactures a broad portfolio of single-use urological catheters and rectal devices, including products that overlap with Consure's catheter-based fecal management category. Its scale, ICU sales relationships, and disposable medical device expertise make it a comparable incumbent threat.
• Medline Industries: Medline is one of the largest privately held medical device and supply manufacturers and distributors, with a portfolio of incontinence management products reaching the same US hospital ICUs Consure targets. Its scale and existing GPO contracts represent both a competitive threat and a potential distribution partner.
• Stryker (Sage Products): Stryker's Sage Products division offers hospital hygiene and skin care solutions for ICU and bedridden patients, addressing overlapping clinical priorities (pressure injury prevention, incontinence-associated dermatitis) with Consure's fecal management systems.
• Becton Dickinson (BD): BD (formerly Bard) has historical leadership in urological and rectal catheter products and a global hospital sales infrastructure. Its legacy fecal management catheter offerings compete with Consure's products in the same ICU channel.

Regional players

• Cardinal Health: Cardinal Health distributes a broad range of incontinence and catheter products across US hospitals and provides supply chain services relevant to Consure's go-to-market. While primarily a distributor, its private-label incontinence products overlap with Consure's category.

Others

• 3M Health Care: 3M's Health Care division includes advanced wound care and skin integrity products used in the same ICU population Consure targets to prevent pressure injuries and IAD. While not a direct fecal management competitor, 3M competes for the same hospital budget allocated to HAPI/HAC reduction programs.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xtwitter.com/ConsureMedical
• YouTubeyoutube.com/channel/UCidqgD8hALAPUX38rZdpaBQ
• Facebookfacebook.com/ConsureMedicalInc
• LinkedInlinkedin.com/company/consure-medical
• Instagraminstagram.com/consuremedical

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Funding overview

Funding rounds4 records

Investors5 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Consure Medical